EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT

Matthias Jackwerth, Severin Mairinger, Ivo Rausch, Maria Weber, Anselm Jorda, Lukas Nics, Werner Langsteger, Markus Zeitlinger, Marcus Hacker, Oliver Langer

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07121-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Matthias Jackwerth und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Probenecid, Positron Emission Tomography Computed Tomography, Whole Body Imaging, Purines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Multidrug resistance-associated proteins (MRPs) have a widespread tissue distribution. They play an important role in drug disposition and drug-drug interactions (DDIs) and have been associated with various diseases. PET with 6-bromo-7-[ 11 C]methylpurine ([ 11 C]BMP) has been used to assess MRP1 function in the brain and lungs of mice. [ 11 C]BMP crosses cellular membranes by passive diffusion followed by intracellular conjugation with glutathione and MRP1-mediated efflux of the radiolabelled glutathione-conjugate. In this study, we assessed the effect of the prototypical organic anion transporter inhibitor probenecid on the whole-body disposition of [ 11 C]BMP to examine its suitability for measuring the function of MRP1 and possibly other MRP subtypes across multiple tissues.

Methods

Seven healthy volunteers (3 women, 4 men) underwent two dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [ 11 C]BMP, without and with pre-treatment with a single oral dose of probenecid. Volumes of interest were outlined for several MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, skeletal muscle, kidneys, and liver). Tissue time-activity curves were corrected for the contribution of vascular radioactivity and the elimination rate constant ( k E , h − 1 ) was calculated as a parameter for tissue MRP function.

Results

Radioactivity was primarily excreted into the urinary bladder and urinary clearance was significantly decreased after probenecid administration (− 50 ± 16%). Following probenecid administration, k E was significantly decreased in the kidneys (− 43 ± 20%), liver (− 18 ± 15%), myocardium (− 16 ± 12%), skeletal muscle (− 51 ± 34%), and retina (− 57 ± 29%, non-blood-corrected).

Conclusion

Our study highlights the great potential of LAFOV PET/CT to assess drug disposition and transporter-mediated DDIs in humans at a whole-body, multi-tissue level. Due to the slow elimination of [ 11 C]BMP-derived radioactivity from the human brain, [ 11 C]BMP appears unsuitable to measure cerebral MRP1 function in humans, but it may be used to assess the function of MRP1 and possibly other MRP subtypes in various peripheral tissues.

Trial registration

EudraCT 2021-006348-29. Registered 15 December 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbenecidPositron Emission Tomography Computed TomographyWhole Body ImagingPurinesHumansMaleFemaleAdultTissue DistributionCarbon RadioisotopesMiddle Aged

Stichwörter der Autor:innen

Drug dispositionLong axial field-of-view PET/CTMembrane transportersProbenecidTransporter-mediated drug-drug interaction

Substanzen

ProbenecidCarbon RadioisotopesPurinesCarbon-11

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
  • QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. oliver.langer@meduniwien.ac.at.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. oliver.langer@meduniwien.ac.at.

Förderung

  • Medical University of Vienna

Zitieren

APA

Jackwerth, M., Mairinger, S., Rausch, I., Weber, M., Jorda, A., Nics, L., Langsteger, W., Zeitlinger, M., Hacker, M., & Langer, O. (2025). Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07121-5

Vancouver

Jackwerth M, Mairinger S, Rausch I, Weber M, Jorda A, Nics L, et al. Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07121-5

BibTeX
@article{Jackwerth2025,
  author = {Jackwerth, Matthias and Mairinger, Severin and Rausch, Ivo and Weber, Maria and Jorda, Anselm and Nics, Lukas and Langsteger, Werner and Zeitlinger, Markus and Hacker, Marcus and Langer, Oliver},
  title = {Effect of probenecid on the whole-body disposition of 6-bromo-7-[11C]methylpurine in humans assessed with long axial field-of-view PET/CT},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07121-5}
}
Kostenlos starten →